Cipla eyes global on-ground presence with US, Brazil, Turkey on radar
This article was originally published in Scrip
More details of the strategic evolution underway at Cipla, traditionally known for its risk-averse global partnerships-only approach and lack of off-shore presence despite its products being available worldwide, are emerging. The Indian firm has now indicated its intent for its own set-up in the US and an expansion across a clutch of smaller markets.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.